Literature DB >> 9122087

Reversible acute renal failure induced by losartan in a renal transplant recipient.

M Ostermann1, D J Goldsmith, T Doyle, J C Kingswood, P Sharpstone.   

Abstract

A 56-year-old man who received a live-related renal transplant in 1988 was started in 1995 on the selective angiotensin II antagonist losartan (Dupont-Merke) to treat worsening hypertension. Two months later because of pulmonary oedema, loop diuretics were started. Within two weeks, serum creatinine had increased from 245 to 571 mumol/l, and the patient became oliguric. A systolic bruit was noted over the graft. Renal angiography showed a 90% stenosis of the transplant renal artery. Losartan was withdrawn, with prompt improvement in renal function. A successful percutaneous transluminal angioplasty performed a few days later resulted in further improvement in renal function accompanied by a significant diuresis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9122087      PMCID: PMC2431233          DOI: 10.1136/pgmj.73.856.105

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  2 in total

Review 1.  Angiotensin receptor antagonists: focus on losartan.

Authors:  C I Johnston
Journal:  Lancet       Date:  1995-11-25       Impact factor: 79.321

2.  Losartan-induced azotemia in a diabetic recipient of a kidney transplant.

Authors:  L S Cohen; E A Friedman
Journal:  N Engl J Med       Date:  1996-05-09       Impact factor: 91.245

  2 in total
  3 in total

Review 1.  Renal artery stenosis as a cause of renal impairment: implications for treatment of hypertension and congestive heart failure.

Authors:  J E Scoble
Journal:  J R Soc Med       Date:  1999-10       Impact factor: 5.344

2.  Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis.

Authors:  T L Johansen; A Kjaer
Journal:  BMC Nephrol       Date:  2001-05-17       Impact factor: 2.388

3.  Utilisation and Tolerability of Aliskiren in the Primary Care Setting in England.

Authors:  Abigail L Coughtrie; Claire Doe; Deborah Layton; Saad A W Shakir
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-06-03       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.